Myriam Curet McAdams - 26 Jan 2024 Form 4 Insider Report for INTUITIVE SURGICAL INC (ISRG)

Role
EVP & Chief Medical Officer
Signature
By: Donna Spinola For: Curet, Myriam
Issuer symbol
ISRG
Transactions as of
26 Jan 2024
Net transactions value
-$822,482
Form type
4
Filing time
29 Jan 2024, 17:32:24 UTC
Previous filing
02 Jan 2024
Next filing
13 Feb 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ISRG Common Stock Options Exercise $501,567 +2,818 +1491% $177.99 3,007 26 Jan 2024 Direct F1
transaction ISRG Common Stock Sale $1,043,077 -2,818 -94% $370.15 189 26 Jan 2024 Direct F1, F2
transaction ISRG Common Stock Options Exercise $274,250 +1,500 +794% $182.83 1,689 26 Jan 2024 Direct F1
transaction ISRG Common Stock Sale $555,222 -1,500 -89% $370.15 189 26 Jan 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ISRG Non-Qualified Stock Option (right to buy) Options Exercise $0 -2,818 -26% $0.000000 7,893 26 Jan 2024 Common Stock 2,818 $177.99 Direct F1, F3
transaction ISRG Non-Qualified Stock Option (right to buy) Options Exercise $0 -1,500 -17% $0.000000 7,500 26 Jan 2024 Common Stock 1,500 $182.83 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These shares were sold in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 12, 2024.
F2 The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $368.45 to $371.65 as follows: 1,100 shares sold at $368.45 to $369.45; 1.800 shares sold at $369.54 to $370.52; and 1,418 shares sold at $370.65 to $371.65. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
F3 Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.